What if your experience could help brain tumour survivors make friends? Take part in a 1-hour discussion group (online)

Eligibility: Between the ages of 8-16 years, diagnosed with a brain tumour, completed active treatment at least one year ago, speaks English or French. (Parents will also be asked to complete a questionnaire)

Contact: bt.focus.hsj@ssss.gouv.qc.ca

The main goal of the STRATUM project is to develop a 3D decision-support tool for brain surgeries, based on the processing of multimodal data through artificial intelligence algorithms.

The project follows a co-creation methodology, actively involving end-users—mainly neurosurgeons—as well as other key stakeholders in brain surgery, such as radiologists and anesthesiologists.

Eligibility: Neurosurgeons, Radiologists and Anesthesiologists

Survey and contact information: https://ec.europa.eu/eusurvey/runner/STRATUM_cocreation_survey

Contact: Dr Álvarez-Malé – marialuisa.alvarez@fpct.ulpgc.es

With recent advances in medical treatment, many children diagnosed with a brain tumour are cured. However, survivors often experience learning problems as a result of treatment. Right now, we don’t know a lot about therapies that can help thinking skills and the brain recover after treatment for a brain tumour. Metformin shows great promise in helping the brain recover from damage and improve cognitive function. Drs. Donald Mabbott and Eric Bouffet from The Hospital for Sick Children (SickKids) in Toronto, Ontario, Canada, are leading a group of researchers across Canada and Australia in a double-blind, placebo-controlled trial using cognitive testing and novel brain scanning to see if metformin can improve thinking skills and help the brain grow in pediatric brain tumour survivors.

Eligibility: Your child is eligible to participate in the study if they:

• Have finished primary therapy (minimum 3 weeks after end of therapy) for a brain tumour such as medulloblastoma, ependymoma, craniopharyngioma, germ cell tumour, or other brain tumour treated with cranial radiation OR relapsed ependymoma treated with cranial radiation
• Are between 7 and 21 years of age
• Have English as their native language or have had at least two years of schooling in English
• Are able to swallow tablets either whole or crushed or via feeding tube
• Meet criteria for adequate organ function requirements

Your child is not eligible to participate in the study if they:

• Have an IQ of less than 60 on screening test
• Have a known hypersensitivity to metformin
• Have unstable and/or insulin-dependent (Type 1) diabetes
• Have a history of renal (kidney) disease or malfunction, or congestive heart failure
• Are taking part in another intervention study
• Are currently using metformin
• Are on palliative care

Contact: Email metmedcan.main@sickkids.ca if you are interested in participating and/or would like more information about the study.

Researchers at Leeds Beckett University (UK) are conducting a study exploring the effects of non-pharmacological interventions (e.g., exercise and music therapy) on the quality of life of individuals living beyond a childhood brain tumour. The study will involve participation in a focus group and two weeks of audio diary submissions via WhatsApp (~3 entries per week). In addition to contributing to knowledge about the best approaches to support those living beyond a childhood brain tumour, participants will receive a £40 (or equivalent) gift voucher as a thank-you for their participation.

Eligibility: To participate, individuals must have been diagnosed with a brain tumour during childhood and be 18 years of age or older.

Participants living outside the UK are welcome, as focus groups can be conducted online and audio diary entries can be submitted using a smartphone.

Contact: For more information about the study, please contact Dr Ollie Williamson at o.williamson@leedsbeckett.ac.uk.

CAN-PACT (Canadian Network for Psychedelic-Assisted Cancer Therapy) is inviting specific voices to take part in a short survey to help identify the top unanswered questions about psychedelic-assisted cancer therapies. Your questions will help guide future research priorities, and your voice is safe and valued in this 15-minute online survey.

Eligibility: People with current or past cancer, Caregivers supporting someone with cancer, Clinicians working in oncology, any discipline, Healthcare policymakers, 18+ and living in Canada

Survey and contact for questions: https://survey.ucalgary.ca/jfe/form/SV_czITXUHWzlAsUtM

Questions? Contact Nisha Marshall at nisha.marshall@ucalgary.ca.

We are looking for Canadian parents/caregivers of a childhood cancer survivor to participate in this 7-week, online group intervention co-designed with parents to help them manage their fear of cancer recurrence

Who is Eligible: Parents of a childhood cancer survivor who worry their child’s cancer may come back, the child is at least 1 month from the completion of treatment, less than 18 years of age and has not experienced a cancer recurrence.

For more information: choly@uottawa.ca

Join this study on the sexual health of cancer survivors in Canada.  This is a 30-minute survey covering demographics, cancer history and sexual health.

Eligibility: Individuals diagnosed with cancer within the last 5 years who are 19 years or older and living in Canada for the past 5 years.

For more information and to participate, click here.

Researchers at the University of Calgary are conducting a study to explore how patient and physician factors—such as background, experiences, and personal beliefs—influence shared treatment decision-making. The study seeks to better understand patients’ experiences and challenges when making treatment decisions with their oncologists, as well as their perspectives on what an ideal treatment discussion would look like.

Participants in the study will be asked to complete two questionnaires that include questions about socio-demographic background, psychological factors, and details of their cancer diagnosis. They will also take part in one focus group (approximately 90 minutes) with other cancer patients and survivors.
As a token of appreciation, participants will receive a $25 gift card for sharing their insights and experiences.

Who is eligible to participate?

• Adults (18+) diagnosed with cancer within the past two years (2023 – present)
• Living in Alberta
• Referred to a medical oncologist for a chemotherapy assessment
• Comfortable using Zoom videoconferencing software

For more information, please email Madison Leia at Madison.leia1@ucalgary.ca.

This study will explore knowledge, insights, and needs related to cancer-related cognitive impairment (also known as “brain fog”) in order to inform more tailored psychosocial supports. Participation involves a short online survey (10 minutes) and a virtual interview (30–60 minutes).

Who is eligible to participate?

Ontario-based individuals living with and beyond a malignant cancer diagnosis (any age, type, or stage) who have Internet access and can communicate in English.

For more information, please email Sitara Sharma (PhD Student) at sitara.sharma@uottawa.ca.

We are UBC researchers studying how cancer patients feel about the use of artificial intelligence (AI) in their care, especially when it comes to predicting life expectancy. Through one-on-one interviews, either in-person or virtually, we hope to learn about patients’ thoughts, expectations, comfort levels, and any concerns they may have about using AI in medical decisions. By gathering the experiences of people receiving cancer care, we aim to better understand how patients view these new technologies. Our findings will help improve patient education, support clear communication, and guide the use of AI tools to benefit patient care and outcomes.

Who is eligible to participate?

To participate in this study, you much be a patient with a cancer diagnosis (of any stage and any type), be 18 years or older, have the capacity to make decisions, and reside in British Columbia.

For more information please contact Anita Ho, PhD, MPH (Principal Investigator) at anita.ho@ubc.ca or Nikolay Alabi, BS (Co-Investigator) at nalabi60@student.ubc.ca

We hope to enroll 2000 people to get a complete picture of what it means to have cancer as a young adult right now. The information you provide will be used to increase awareness and develop programs to address the issues that Young Adults with cancer feel are most important. People living in Canada who are over the age of 18 and were diagnosed with any type of cancer before the age of 40. You will complete an online survey once a year for up to five years. Each survey will take approximately 30-45 minutes to complete.

All you have to do is complete the following link:

complete study

Once we confirm your eligibility, you will receive an email with a unique link to complete the survey.

For more information – research@youngadultcancer.ca

The study, conducted by the Injury Prevention Research Office and St. Michael’s Hospital in Toronto, Canada aims to measure the effect of visual symptoms on the quality of life in patients with pituitary tumors. Visual symptoms are one of the most common effects of large pituitary tumors. This study is aimed to develop a tool to better measure the effect of these visual symptoms on a pituitary tumor patient’s ability to function in daily life. Anyone who is currently/or has ever been diagnosed with a pituitary tumor. If you are interested in participating in the study by completing the survey, click here. This survey should take about 45 minutes to complete.

If you have any other questions, please feel free to contact us at: injuryprevention@smh.ca

The purpose of this study is to discover why some people develop LGG while other people do not. We also hope to learn more about the effect of this diagnosis and the associated treatments on daily life including the ability to work, drive, sleep, exercise, or take care of oneself and/or family. Any person over the age of 20 years with an initial diagnosis of LGG. Postmortem tissue samples and pathology reports may also be eligible for inclusion in the study. Please email for more information.

For more information: email the study at: glioma@yale.edu